Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — Q3 2019 Earnings Presentation
19 slides from Hyphens Pharma International's earnings presentation, Nov 19, 2019
Slide 1: General Announcement: Hyphens Press Release 3Q2019
11/20/2019 General Announcement::Hyphens Press Release 3Q2019 Issuer & Securities GENERAL ANNOUNCEMENT::HYPHENS PRESS RELEASE 3Q2019 Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement
Slide 2: Hyphens Pharma International Limited Results Briefing 3Q2019
Hyphens Pharma International Limited Results Briefing 3Q2019 HYPHENS PHARMA INTL LTD (SGX: 1J5)
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Corporate Information
CORPORATE INFORMATION Shareholding Public Float3, 19.7% Bloomberg Code HYP:SP Reuters Code 1J5.SI ISIN Code 1J5 Issued Shares (M) 300.43 Executive Market Cap (SG$M) (15 Nov 2019) 60.1 Director², Inomed 14.6% Holding¹, Share Price (SG$) (15 Nov 2019) 0.20 65.4% Average volume 1-mth (‘000) 110.7 52 wk
Slide 5: Key Developments 3Q2019
KEY DEVELOPMENTS 3Q2019 4
Slide 6: Board of Directors Reinforced
BOARD OF DIRECTORS REINFORCED Ms Tan Seok Hoong @ Mrs Audrey Liow was appointed to our Board as Independent Director on 29 July 2019. Having spent 30 years with the Nestlé Group, Audrey has in-depth experience and international background in marketing, management and operations in the food, nutritio
Slide 7: Corporate Team Strengthened
CORPORATE TEAM STRENGTHENED Yann Marche Sarah Wong Jessica Tan Chief Operating Officer Marketing Director Senior Regional HR Manager
Slide 8: Atopic Dermatitis Range
ATOPIC DERMATITIS RANGE Gentle Non-Soap Wash Maintenance Therapy Enriched with Essential Skin Lipids in a pH Balanced System * NEW! Specially-Formulated Triple Protective Action Menthol Gel to Calm & Ceramide-Dominant Mosquito Repellent For AD Against Diaper Rash Soothe Itchy Skin Therapeutic Moistu
Slide 9: Ceradan OTC Drive
CERADAN OTC DRIVE In pharmacy in Jurong Point xxx
Slide 10: Ceradan OTC Drive
CERADAN OTC DRIVE Top shelf display Video ad
Slide 11: Increased Research Coverage
INCREASED RESEARCH COVERAGE
Slide 12: Financial Highlights
FINANCIAL HIGHLIGHTS 11
Slide 13: Income Statement
INCOME STATEMENT S$’000 3Q2019 3Q2018 Change % 9M2019 9M2018 Change % Revenue 30,699 29,448 4.2% 86,705 90,963 -4.7% Gross profit 10,873 9,499 14.5% 30,497 30,209 1.0% Opex 8,886 8,126 9.4% 24,914 24,630 1.2% EBITDA 2,712 1,634 66.0% 7,424 6,448 15.1% Profit before tax 2,209 1,433 54.2% 5,924 5,817
Slide 14: Segment Revenue
SEGMENT REVENUE 9M2019 9M2018 Medical Hypermart & Digital 29,682; 29,067; 34% 32% 46,370; 51,818; 54% 57% 10,653; 10,078; 12% 11% Proprietary Specialty Pharma Brands Principals Figs in S$’000
Slide 15: Quarterly Revenue
QUARTERLY REVENUE S$’000 35,000 30,886 29,967 30,699 30,000 29,448 29,002 27,004 9,300 10,210 25,000 9,287 10,187 9,730 9,742 20,000 3,386 3,089 3,589 3,315 3,638 15,000 3,426 10,000 18,200 17,591 16,900 15,946 15,634 13,836 5,000 0 2Q2018 3Q2018 4Q2018 1Q2019 2Q2019 3Q2019 Specialty Pharma Principa
Slide 16: Financial Position & Cash Flow
FINANCIAL POSITION & CASH FLOW S$’000 As at 30 Sep 2019 As at 31 Dec 2018 Total assets 78,608 74,979 Cash & cash equivalents 23,456 22,353 Total liabilities 36,178 35,817 Financial liabilities 500 3,000 Total equity 42,430 39,162 NAV per share (cents) 14.12 13.05 S$’000 3Q2019 3Q2018 9M2019 9M2018 C
Slide 17: Financial Ratios
FINANCIAL RATIOS As at 30 Sep 2019 As at 31 Dec 2018 Current ratio 1.95 1.80 Debt-to-Equity ratio 0.85 0.91 ROE 13.38%(1) 13.8% EV/EBITDA 4.15(1)(2) 4.95(2) PE ratio 10.53(1)(2) 10.82(2) PB ratio 1.41(1)(2) 1.49(2) (1) Based on 12-month trailing PAT & EBITDA (2) Based on closing share prices of S$0.
Slide 18: Future Growth
FUTURE GROWTH • Investment in Hyphens Dermatology − Strengthening S&M teams to drive sales − Drive both ethical and consumer healthcare channels − R&D for new products, improve formulation and generate scientific validation • New product launches - Continue to enhance product offerings through licen
Slide 19: Hyphens Pharma International Limited contact
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — Q3 2019 Earnings Presentation on 6ix